What are safe migraine prophylaxis and acute treatment options during pregnancy for a patient taking Qulipta (atogepant) daily before conception?

Migraine Treatment During Pregnancy: Discontinue Qulipta and Transition to Safer Alternatives

Qulipta (atogepant) must be discontinued immediately upon pregnancy recognition, as there is no safety data for CGRP antagonists during pregnancy, and the FDA label does not address pregnancy use. 1

Discontinuing Qulipta

• Stop atogepant immediately when pregnancy is confirmed or suspected, as CGRP receptor antagonists lack adequate human pregnancy safety data 1, 2
• The 2025 American College of Physicians guideline explicitly states that CGRP antagonists-gepants should only be used in "nonpregnant outpatient adults" 3
• While one case report showed no adverse effects with erenumab exposure in early pregnancy, this involved discontinuation by week 2, not continued use throughout pregnancy 2

Acute Migraine Treatment During Pregnancy

For acute migraine attacks, use acetaminophen (paracetamol) as first-line therapy throughout all trimesters. 4

First-Line Acute Treatment

• Acetaminophen (paracetamol) is the preferred medication despite relatively poor efficacy, as it has the best safety profile across all trimesters 4, 5

Second-Line Acute Treatment

• NSAIDs (ibuprofen, naproxen) can be used ONLY during the second trimester 4
• NSAIDs are contraindicated in the first trimester (teratogenic risk) and third trimester (risk of premature ductus arteriosus closure, oligohydramnios, and delayed labor) 4, 5

Third-Line Acute Treatment

• Triptans (particularly sumatriptan) should be used only under strict specialist supervision when acetaminophen and NSAIDs fail 4
• Sumatriptan has the most safety data from post-marketing surveillance, though evidence remains limited 4, 5
• The 2025 ACP guideline emphasizes discussing adverse effects of pharmacologic treatments with pregnant patients 3

Adjunctive Treatment for Nausea

• Metoclopramide can be used for migraine-associated nausea during pregnancy 4

Migraine Prophylaxis During Pregnancy

Preventive medications are best avoided during pregnancy, but if clinically necessary due to frequent disabling attacks, propranolol is the first choice. 4

When Prophylaxis is Indicated

• Consider preventive therapy only when patients experience at least three prolonged severe attacks per month that are particularly incapacitating or unresponsive to acute therapy 6
• Non-pharmacologic approaches should be attempted first 4

First-Line Prophylaxis (if absolutely necessary)

• Propranolol has the best available safety data and should be used under specialist supervision to monitor potential fetal harm 4
• Typical dosing: 80-160 mg daily in long-acting formulations 4

Second-Line Prophylaxis (if propranolol contraindicated)

• Amitriptyline can be considered as an alternative, also requiring specialist supervision 4
• Dosing: 10-100 mg orally at night 4

Absolutely Contraindicated Prophylactic Agents

• Sodium valproate is absolutely contraindicated due to known teratogenicity 4
• Topiramate is contraindicated due to adverse fetal effects 4
• Candesartan is contraindicated due to adverse fetal effects 4
• All CGRP antagonists (including atogepant/Qulipta) should be avoided due to lack of safety data 3, 1

Non-Pharmacologic Management

Emphasize lifestyle modifications as the foundation of migraine management during pregnancy. 3

• Maintain adequate hydration 3
• Regular meals to avoid hypoglycemia 3
• Consistent sleep schedule with sufficient duration 3
• Regular moderate-to-intense aerobic exercise (as pregnancy permits) 3
• Stress management through relaxation techniques or mindfulness practices 3
• Identify and avoid specific migraine triggers 3
• Bed rest alone may suffice for some attacks 4

Critical Counseling Points

• Discuss the risks versus benefits of all pharmacologic treatments during pregnancy and lactation with the patient 3
• Many women experience spontaneous improvement or remission of migraines during pregnancy, particularly in the second and third trimesters, especially those with menstrual migraines or migraines without aura 7, 5
• Approximately 50% or more of pregnant women with migraine see symptom improvement 7, 5
• Postpartum recurrence is common due to drops in estradiol and endorphin levels 7
• Untreated severe migraines with frequent nausea, vomiting, and dehydration may pose maternal and fetal risks that outweigh medication risks 6

Common Pitfalls to Avoid

• Do not use opioids or butalbital for acute migraine treatment, even during pregnancy 3
• Do not continue CGRP antagonists based on limited case report data; the risk-benefit ratio is unfavorable given lack of systematic safety data 2
• Do not use NSAIDs in the first or third trimester despite their effectiveness 4
• Avoid medication overuse headache by limiting acute medication use (≥15 days/month for NSAIDs/acetaminophen; ≥10 days/month for triptans) 3